Clomiphene Citrate Market, by Indication (PCOS, Secondary Amenorrhea, Psychogenic Amenorrhea, Amenorrhea Galactorrhea Syndrome, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North Amer

Clomiphene Citrate Market, by Indication (PCOS, Secondary Amenorrhea, Psychogenic Amenorrhea, Amenorrhea Galactorrhea Syndrome, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

According to the data published in the National Institutes of Health (NIH) in January 2017, the most common overall cause of female infertility is the failure to ovulate, which occurs in 40% of women with infertility issues, globally. To treat such infertility problems in females, clomiphene citrate is the first choice of medicine for the past 40 years, according to the Global Library of Women’s Medicine. Gynecologists prescribe clomiphene for 1 to 6 months or more with a low dose of 50 mg daily (1 tablet) for 5 days. If ovulation does not occur after the first course of therapy, a second course of 100 mg daily (two 50 mg tablets given as a single daily dose) for 5 days is prescribed.
According to a study called ‘Clomiphene citrate usage pattern in India' conducted by Fertility Science and Research in 2014, ovulation rate was reported to increase from 21% to 60% and the pregnancy rate was noticed to be increased by 11% to 30% by majority of participants. The ovulation rate and pregnancy rate was increased using clomiphene citrate because of increased secretion of hypothalamic gonadotropin-releasing hormone (GnRH) to increase the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which will, in turn, stimulate ovarian follicular activity.
Market Dynamics
High incidence of polycystic ovarian syndrome is expected to be a key driver for the clomiphene citrate market growth. For instance, according to an article published in 2014 in Clinical Epidemiology, polycystic ovarian syndrome affects 8% to 20% of the reproductive-age women, globally. According to the World Health Organization, in 2012, polycystic ovarian syndrome affected 116 million women, worldwide.
The clomiphene citrate market growth is hindered by side effects shown by this drug, which includes headache, nausea, upper respiratory tract infection, abdominal tenderness, sinus congestion, mood swings, acne, breast tenderness, weight gain, pelvic discomfort, abnormal bleeding or spotting, vomiting, injection site pain, redness, dizziness, and ovarian hyper-stimulation syndrome (OHSS). For instance, according to a study published in NCBI, in 2016, 10% to 20% of women who consumed clomiphene citrate developed a mild form of OHSS, which will usually resolve on its own. Severe cases of OHSS occurred in less than one percent of patients in the U.S.
Key features of the study:
This report provides in-depth analysis of the global clomiphene citrate market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global clomiphene citrate market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Sanofi S.A., Par Pharmaceutical, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Unichem Laboratories Ltd., Emcure Pharmaceuticals Ltd., Serum Institute of India Pvt. Ltd., Incepta Pharmaceuticals Ltd., and Shanghai Trifecta Pharma Co. Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global clomiphene citrate market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for clomiphene citrate market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Clomiphene Citrate Market, By Indication:
PCOS
Secondary Amenorrhea
Psychogenic Amenorrhea
Amenorrhea Galactorrhea Syndrome
Others
Global Clomiphene Citrate Market, By Distribution Channel::
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Clomiphene Citrate Market, By Region:
North America
By Country:
U.S.
Canada
By Indication:
PCOS
Secondary Amenorrhea
Psychogenic Amenorrhea
Amenorrhea Galactorrhea Syndrome
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Indication:
PCOS
Secondary Amenorrhea
Psychogenic Amenorrhea
Amenorrhea Galactorrhea Syndrome
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Indication:
PCOS
Secondary Amenorrhea
Psychogenic Amenorrhea
Amenorrhea Galactorrhea Syndrome
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Indication:
PCOS
Secondary Amenorrhea
Psychogenic Amenorrhea
Amenorrhea Galactorrhea Syndrome
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Indication:
PCOS
Secondary Amenorrhea
Psychogenic Amenorrhea
Amenorrhea Galactorrhea Syndrome
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Indication:
PCOS
Secondary Amenorrhea
Psychogenic Amenorrhea
Amenorrhea Galactorrhea Syndrome
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Sanofi S.A.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Par Pharmaceutical
Merck & Co. Inc.
Teva Pharmaceutical Industries Ltd.
Cipla Inc.
Unichem Laboratories Ltd.
Emcure Pharmaceuticals Ltd.
Serum Institute of India Pvt. Ltd.
Incepta Pharmaceuticals Ltd.
Shanghai Trifecta Pharma Co. Ltd.
“*” marked represents similar segmentation in other categories in the respective section.